@article{a4e40370f1a04842a31837d8d3f45c13,
title = "Accelerating stem cell trials for Alzheimer's disease",
abstract = "At present, no effective cure or prophylaxis exists for Alzheimer's disease. Symptomatic treatments are modestly effective and offer only temporary benefit. Advances in induced pluripotent stem cell (iPSC) technology have the potential to enable development of so-called disease-in-a-dish personalised models to study disease mechanisms and reveal new therapeutic approaches, and large panels of iPSCs enable rapid screening of potential drug candidates. Different cell types can also be produced for therapeutic use. In 2015, the US Food and Drug Administration granted investigational new drug approval for the first phase 2A clinical trial of ischaemia-tolerant mesenchymal stem cells to treat Alzheimer's disease in the USA. Similar trials are either underway or being planned in Europe and Asia. Although safety and ethical concerns remain, we call for the acceleration of human stem cell-based translational research into the causes and potential treatments of Alzheimer's disease.",
author = "Hunsberger, {Joshua G.} and Mahendra Rao and Joanne Kurtzberg and Bulte, {Jeff W.M.} and Anthony Atala and LaFerla, {Frank M.} and Greely, {Henry T.} and Akira Sawa and Sam Gandy and Schneider, {Lon S.} and Doraiswamy, {P. Murali}",
note = "Funding Information: We acknowledge the contributions of all faculty members and participants at our meeting for the valuable discussions. We are especially grateful for the support of Marjorie Bekaert Thomas, Trustee for the Karen L Wrenn Trust, whose vision led to this conference. The meeting on stem cells and Alzheimer{\textquoteright}s disease, and the writing of this Personal View, was funded by a gift from the Karen L Wrenn Trust to PMD through Duke University. The Trust had no input in the content of this Personal View. We also acknowledge support from Accelerated Medicines Partnership/U01 AG046170, the David Werber Family Trust, the Cure Alzheimer{\textquoteright}s Fund, and Veterans airs (grant I01RX000684) (all to SG). JWMB, PMD, and AS have been supported by grants from the US National Institutes of Health. JWMB is also supported by the National Multiple Sclerosis Society, the ALS Association, and the Maryland Stem Cell Research Fund. AS reports receiving grants from the Brain & Behavior Research Foundation (formerly the NARSAD), Stanley Foundation, RUSK Foundation, and Maryland Stem Cell Research Funds during the writing of the manuscript. Figure 1 is courtesy of Piotr Walczak and Miroslaw Janowski, Johns Hopkins University, Baltimore, MD, USA. Funding Information: JGH received a fee from Duke University, Durham, NC, USA, for organising the conference. JWMB has received grants from Philips Healthcare and is a co-founder and co-owner of SenCEST, LLC, which is outside the scope of the submitted work. SG has received grants from Constellation, and personal fees from Neurotrope and Focused Ultrasound Foundation outside the submitted work. LSS has consulted with Stemedica Cells, Inc, a developer of therapeutic stem cells. PMD has received advisory fees from Avid/Lilly, Anthrotonix, Muses Labs, AstraZeneca, Abbvie, Baxter, Cognoptix, Lundbeck/Takeda, Piramal, Genomind, Sonexa, Targacept, Danone, Neurocog Trials, EnVivo, and T3D Therapeutics; research grants (through Duke University) from Elan, Avid/Lilly, Janssen, Pfizer/Medivation, Neuronetrix, Forum, Alzheimer's Drug Discovery Foundation, DOD, and ADCS/UCSD; fees for lectures from Lundbeck and the Alzheimer's Association; and fees for developing educational materials from Physicians Postgraduate Press. PMD owns shares or options in Maxwell Health, Muses Labs, Anthrotronix, Evidation, and Adverse Events Inc (whose products are not discussed here), and has received travel funds from Biogen/Xprize and the World Economic Forum. All other authors declare no competing interests. Funding Information: We acknowledge the contributions of all faculty members and participants at our meeting for the valuable discussions. We are especially grateful for the support of Marjorie Bekaert Thomas, Trustee for the Karen L Wrenn Trust, whose vision led to this conference. The meeting on stem cells and Alzheimer's disease, and the writing of this Personal View, was funded by a gift from the Karen L Wrenn Trust to PMD through Duke University. The Trust had no input in the content of this Personal View. We also acknowledge support from Accelerated Medicines Partnership/U01 AG046170 , the David Werber Family Trust, the Cure Alzheimer's Fund, and Veterans Affairs ( grant I01RX000684 ) (all to SG). JWMB, PMD, and AS have been supported by grants from the US National Institutes of Health. JWMB is also supported by the National Multiple Sclerosis Society, the ALS Association, and the Maryland Stem Cell Research Fund. AS reports receiving grants from the Brain & Behavior Research Foundation (formerly the NARSAD), Stanley Foundation, RUSK Foundation, and Maryland Stem Cell Research Funds during the writing of the manuscript. Figure 1 is courtesy of Piotr Walczak and Miroslaw Janowski, Johns Hopkins University, Baltimore, MD, USA. ",
year = "2016",
month = feb,
day = "1",
doi = "10.1016/S1474-4422(15)00332-4",
language = "English (US)",
volume = "15",
pages = "219--230",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "2",
}
